PROCESS FOR MAKING MULTIPARTICULATE GASTRORETENTIVE DOSAGE FORMS

• US 20130217777A1
• Filed: 10/20/2011
• Published: 08/22/2013
• Est. Priority Date: 10/22/2010
• Status: Abandoned Application

• Current Assignee: Meliatys
• Original Assignee: Meliatys
• Inventors: Kirkorian, Joel Sylvain Michel
• Application Number:
  US13/879,990
• Publication Number:
  US 20130217777A1
• Time in Patent Office: Days
• US Class Current: 514/630
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 9/0065 Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
• CPC Class Codes: A61K 9/16 Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The instant invention relates to a process for making inherent low density particles, comprising the steps of (i) providing a powder mixture comprising a swelling agent; (ii) granulating the powder of step (i) with a granulating solution comprising a lipophilic agent into granules and (iii) drying the granules of step (ii). The instant invention further relates to multiparticulate oral gastro-retentive dosage forms comprising the inherent low density particles obtainable by the process.

Claims

1. A process for making low density particles, comprising the steps of:

(i) providing a powder mixture comprising a swelling agent;

(ii) granulating the powder of step (i) with a granulating solution comprising a lipophilic agent into granules;

(iii) drying the granules of step (ii).

2. The process according to claim 1, further comprising the step (iv) of compressing the granules of step (iii).

3. The process according to claim 1, further comprising the step (v) of coating the granules resulting from step (ii) or step (iii).

4. The process according to claim 1, wherein the active ingredient is added into the starting powder of step (i) and/or the granulating solution of step (ii), preferably into the starting powder of step (i) and/or is laid on the granules obtained in step (iii).

5. The process according to claim 1, wherein a binder is added with the starting material in step (i) and/or the granulating solution of step (ii), preferably into the starting powder of step (i).

6. The process according to claim 1, wherein the swelling agent is a cellulose derivative having a molecular weight from 4,000 to 2,000,000, hydroxymethylcellulose, hydroxyethylcellulose hydroxypropyl methylcellulose, superporous hydrogels;

polyethylene oxides, polyethylenes;

polypropylenes;

polyvinyl chlorides;

polycarbonates;

polystyrenes;

polyacrylates;

carboxyvinyl polymers;

polyvinyl alcohols;

glucans;

scleroglucans;

chitosans;

mannas;

galactomannans;

gums;

xantan gums;

carrageenans;

amylase;

alginic acids, acrylates, methacrylates, acrylic/methacrylic copolymers, polyanhydrides, polyamino acids, methyl vinyl ethers/maleic anhydride copolymers, carboxymethylcellulose, carboxymethylcellulose derivatives and copolymers thereof or a water soluble resin and mixture thereof, most preferably selected among polyethylene oxides having a molecular weight of at least 1,000,000 and hydroxypropyl methylcellulose with a molecular weight of at least 100,000 and combinations thereof.

7. The process according to claim 1, wherein the granulating solution is an aqueous solution or dispersion, an organic solvent, a hydrophobic liquid or water, preferably water.

8. The process according to claim 1, wherein the lipophilic agent comprises one or more highly lipophilic excipients selected from the group consisting of hydrophobic dusty powders and lipidic excipients, preferably from the group consisting of talc, hydrophobic silica, magnesium stearate, glicerides, fatty acid esters or fatty acid, preferably talc, stearic acid glicerides and mixtures thereof.

9. The process according to claim 1, wherein the particles comprise:

from 0.01 to 90% of active ingredient;

from 1 to 99% of swelling agent;

from 1 to 60%, of lipophilic agent; and

optionally

from 1 to 20% of binder.

10. The process according to claim 1, wherein the active ingredient is selected from the group consisting of AIDS adjunct agents, alcohol abuse preparations, Alzheimer'"'"'s disease management agents, amyotrophic lateral sclerosis therapeutic agents, analgesics, anesthetics, antacids, antiarythmics, antibiotics, anticonvulsants, antidepressants, antidiabetic agents, antiemetics, antidotes, antifibrosis therapeutic agents, antifungals, antihistamines, antihypertensives, antiinfective agents, antimicrobials, antineoplastics, antipsychotics, antiparkinsonian agents, antirheumatic agents, appetite stimulants, appetite suppressants, biological response modifiers, biologicals, blood modifiers, bone metabolism regulators, cardioprotective agents, cardiovascular agents, central nervous system stimulants, cholinesterase inhibitors, contraceptives, cystic fibrosis management agents, deodorants, diagnostics, dietary supplements, diuretics, dopamine receptor agonists, endometriosis management agents, enzymes, erectile dysfunction therapeutics, fatty acids, gastrointestinal agents, Gaucher'"'"'s disease management agents, gout preparations, homeopathic remedy, hormones, hypercalcemia management agents, hypnotics, hypocalcemia management agents, immunomodulators, immunosuppressives, ion exchange resins, levocarnitine deficiency management agents, mast cell stabilizers, migraine preparations, motion sickness products, multiple sclerosis management agents, muscle relaxants, narcotic detoxification agents, narcotics, nucleoside analogs, non-steroidal anti-inflammatory drugs, obesity management agents, osteoporosis preparations, oxytocics, parasympatholytics, parasympathomimetics, phosphate binders, porphyria agents, psychotherapeutic agents, radio-opaque agents, psychotropics, sclerosing agents, sedatives, sickle cell anemia management agents, smoking cessation aids, steroids, stimulants, sympatholytics, sympathomimetics, Tourette'"'"'s syndrome agents, tremor preparations, urinary tract agents, vaginal preparations, vasodilators, vertigo agents, weight loss agents, Wilson'"'"'s disease management agents, and mixtures thereof and preferably is selected from the group consisting of abacavir sulfate, abacavirsulfate/lamivudine/zidovudine, acetazolamide, acetaminophen, acyclovir, albendazole, albuterol, aldactone, allopurinol BP, Aluminium carbonate, Aluminium hydroxide, amoxicillin, amoxicillin/clavulanate potassium, amprenavir, artesunate, atovaquone, atovaquone and proguanil hydrochloride, atracurium besylate, baclofen, barium sulfate, beclomethasone dipropionate, berlactone betamethasone valerat, betaï

ne, Bismuth subsalicylate, bupropion hydrochloride, bupropion hydrochloride SR, Calcium carbonate, carbamazepin, carbidopa, carvedilol, caspofungin acetate, cefaclor, cefazolin, ceftazidime, cé

furoxime, chlorambucil, chloroquin, chlorpromazine, cimetidine, cimetidine hydrochloride, ciprofloxacine, cisatracurium besilate, clobetasol propionate, co-trimoxazole, colfoscerilpalpitate, dextroamphetamie sulfate, dioxin, dihydroxyartemisinin, doxycycline, enalapril maleat, epoprostenol, esomepraxole magnesium, fluticasone propionate, furosemide, gabapentin, glitazones, hydrotalcite, hydrocodone hydrochlorothiazide/triamterene, lamivudine, lamotrigine, levodopa, lithium carbonate, lomefloxacine, losartan potassium, Magnesium aluminate monohydrate melphalan, mercaptopurine, mefloquine mesalazine, metformine, morphin, mupirocin calcium cream, nabumetone, naratriptan, norfloxacine, ofloxacine, omeprazole, ondansetron hydrochloride, ovine, oxiconazole nitrate, oxycodone, paroxetine hydrochloride, pefloxacine, piroxicam, prazodin, prochlorperazine, procyclidine hydrochloride, pyrimethamine, ranitidine bismuth citrate, ranitidine hydrochloride, repaglinide, rofecoxib, ropinirole hydrochloride, rosiglitazone maleat, salmeterol xinafoate, salmeterol, fluticasone propionate, Sodium bicarbonate, sterile ticarcillin disodium/clavulanate potassium, simeticon, simvastatin, spironolactone, statins, succinylcholine chloride, sumatriptan, tapentadol, thioguanine, tirofiban hydrochloride, topotecan hydrochloride, tramadol, tranylcypromine sulfate, trifluoperazine hydrochloride, valacyclovir hydrochloride, vinorelbine, zaleplon, zanamivir, zidovudine, zidovudine or lamivudine, corresponding salts thereof, or mixtures thereof, and is most preferably metformin, glitazones, tramadol, tapentadol, oxycodone, hydromorphone and especially with acetaminophen.

11. The process according to claim 1, wherein the inherent low density particles have a density below 1, preferably below 0.9 and more preferably below 0.8, and preferably have an intrinsic porosity.

12. The process according to claim 1, wherein the inherent low density particles are further processed into an oral solid gastro-retentive dosage form in a tablet, a capsule or a sachet.

13. A multiparticulate oral gastro-retentive dosage form in a tablet, a capsule or a sachet, comprising low-density particles obtainable by the process according to any of the preceding claims.

14. The multiparticulate sustained release dosage form according to claim 13 in the form of a tablet.

15. The multiparticulate sustained release dosage form according to claim 13 wherein the particles have a porosity of from 10 to 80%, preferably of from 20 to 70% of the volume of the form.